CN110072849A - 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型 - Google Patents

3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型 Download PDF

Info

Publication number
CN110072849A
CN110072849A CN201780077637.2A CN201780077637A CN110072849A CN 110072849 A CN110072849 A CN 110072849A CN 201780077637 A CN201780077637 A CN 201780077637A CN 110072849 A CN110072849 A CN 110072849A
Authority
CN
China
Prior art keywords
crystal form
nintedanib
ray powder
powder diffraction
diffraction collection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780077637.2A
Other languages
English (en)
Inventor
刘飞
张翠霞
姜伟明
赖清裕
阮新
张豪龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allgenesis Biotherapeutics Inc
Original Assignee
Allgenesis Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allgenesis Biotherapeutics Inc filed Critical Allgenesis Biotherapeutics Inc
Priority to CN202310090866.5A priority Critical patent/CN116063221A/zh
Publication of CN110072849A publication Critical patent/CN110072849A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)

Abstract

多种3‑Z‑[1‑(4‑(N‑((4‑甲基‑哌嗪‑1‑基)‑甲羰基)‑N‑甲基‑氨基)‑苯氨基)‑1‑苯基‑亚甲基]‑6‑甲氧羰基‑2‑吲哚满酮的游离碱晶型及其制备方法，还提供了含有所述晶型的药物制剂及其用于治疗疾病特别是用于治疗血管生成性眼部疾病的用途。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN201780077637.2A 2017-03-14 2017-03-14 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型 Pending CN110072849A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310090866.5A CN116063221A (zh) 2017-03-14 2017-03-14 尼达尼布的晶型

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/076648 WO2018165865A1 (zh) 2017-03-14 2017-03-14 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310090866.5A Division CN116063221A (zh) 2017-03-14 2017-03-14 尼达尼布的晶型

Publications (1)

Publication Number Publication Date
CN110072849A true CN110072849A (zh) 2019-07-30

Family

ID=63523471

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310090866.5A Pending CN116063221A (zh) 2017-03-14 2017-03-14 尼达尼布的晶型
CN201780077637.2A Pending CN110072849A (zh) 2017-03-14 2017-03-14 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310090866.5A Pending CN116063221A (zh) 2017-03-14 2017-03-14 尼达尼布的晶型

Country Status (5)

Country Link
US (1) US10961203B2 (zh)
EP (1) EP3597636A4 (zh)
JP (2) JP7306697B2 (zh)
CN (2) CN116063221A (zh)
WO (1) WO2018165865A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114340618A (zh) * 2019-09-10 2022-04-12 克劳德布雷克医疗有限责任公司 减轻与翼状胬肉相关的对眼外观的担忧的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116063221A (zh) * 2017-03-14 2023-05-05 新源生物科技股份有限公司 尼达尼布的晶型
CN113024439A (zh) * 2021-03-28 2021-06-25 郑州大学 尼达尼布乙磺酸盐新晶型ⅰ的制备

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101883756A (zh) * 2007-12-03 2010-11-10 贝林格尔.英格海姆国际有限公司 制备二氢吲哚酮衍生物的方法
CN104262232A (zh) * 2014-09-09 2015-01-07 苏州明锐医药科技有限公司 尼泰达尼的制备方法
CN104844499A (zh) * 2015-06-05 2015-08-19 北京康立生医药技术开发有限公司 一锅法制备尼达尼布的合成方法
CN105461609A (zh) * 2015-12-25 2016-04-06 杭州新博思生物医药有限公司 一种尼达尼布的制备方法
CN105837493A (zh) * 2016-04-08 2016-08-10 东南大学 尼达尼布的合成方法及其中间体
WO2016178064A1 (en) * 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
WO2016209555A1 (en) * 2015-06-22 2016-12-29 Allgenesis Biotherapeutics Inc. Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
WO2017016530A1 (en) * 2015-07-29 2017-02-02 Zentiva, K.S. A method for preparing methyl (z)-3-[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl] amino]phenyl]amino]phenylmethylene)-oxindole-6-carboxylate (intedanib, nintedanib)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10233500A1 (de) * 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
CN106008308A (zh) * 2015-03-13 2016-10-12 正大天晴药业集团股份有限公司 尼达尼布乙磺酸盐结晶
WO2017077551A2 (en) * 2015-11-03 2017-05-11 Mylan Laboratories Limited An amorphous nintedanib esylate and solid dispersion thereof
WO2017083788A1 (en) * 2015-11-14 2017-05-18 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
CN106748961A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的杂质化合物、制备方法、应用及其检测方法
CN106748960A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的潜在杂质化合物、制备方法、应用及其检测方法
CN116063221A (zh) 2017-03-14 2023-05-05 新源生物科技股份有限公司 尼达尼布的晶型

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101883756A (zh) * 2007-12-03 2010-11-10 贝林格尔.英格海姆国际有限公司 制备二氢吲哚酮衍生物的方法
CN104262232A (zh) * 2014-09-09 2015-01-07 苏州明锐医药科技有限公司 尼泰达尼的制备方法
WO2016178064A1 (en) * 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
CN104844499A (zh) * 2015-06-05 2015-08-19 北京康立生医药技术开发有限公司 一锅法制备尼达尼布的合成方法
WO2016209555A1 (en) * 2015-06-22 2016-12-29 Allgenesis Biotherapeutics Inc. Ophthalmic formulations of tyrosine kinase inhibitors, methods of use thereof, and preparation methods thereof
WO2017016530A1 (en) * 2015-07-29 2017-02-02 Zentiva, K.S. A method for preparing methyl (z)-3-[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl] amino]phenyl]amino]phenylmethylene)-oxindole-6-carboxylate (intedanib, nintedanib)
CN105461609A (zh) * 2015-12-25 2016-04-06 杭州新博思生物医药有限公司 一种尼达尼布的制备方法
CN105837493A (zh) * 2016-04-08 2016-08-10 东南大学 尼达尼布的合成方法及其中间体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114340618A (zh) * 2019-09-10 2022-04-12 克劳德布雷克医疗有限责任公司 减轻与翼状胬肉相关的对眼外观的担忧的方法

Also Published As

Publication number Publication date
EP3597636A4 (en) 2020-10-21
JP7306697B2 (ja) 2023-07-11
JP2020508979A (ja) 2020-03-26
WO2018165865A1 (zh) 2018-09-20
EP3597636A1 (en) 2020-01-22
US20200002294A1 (en) 2020-01-02
JP2021176899A (ja) 2021-11-11
US10961203B2 (en) 2021-03-30
CN116063221A (zh) 2023-05-05

Similar Documents

Publication Publication Date Title
CN110072849A (zh) 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-氨基)-苯氨基)-1-苯基-亚甲基]-6-甲氧羰基-2-吲哚满酮的晶型
CA2893423C (en) Nematicidal aqueous suspension concentrate compositions
CN103249305A (zh) 使用前药形式的激酶抑制剂化合物治疗眼科疾病的方法
CN110506740B (zh) 一种抗冲刷、高持留的农药微球及其制备方法
CN103141485B (zh) 一种含多效唑和甲哌鎓的植物生长调节剂及制剂制备方法
CN105073731A (zh) 植物生长调节化合物
Ebian et al. Effect of additives on the kinetics of interconversion of sulphamethoxydiazine crystal forms
CN111019220B (zh) 一种应用于种衣剂成膜剂的低分子量聚烯烃乳液及其制备方法
TWI632133B (zh) ３－ｚ－［１－（４－（ｎ－（（４－甲基－哌嗪－１－基）－甲羰基）－ｎ－甲基－胺基）－苯胺基）－１－苯基－亞甲基］－６－甲氧羰基－２－吲哚啉酮的晶型
CN101374839A (zh) 适用作詹纳斯激酶抑制剂的吖吲哚类
TWI676617B (zh) 3-z-[1-(4-(n-((4-甲基-呱嗪-1-基)-甲羰基)-n-甲基-胺基)-苯胺基)-1-苯基-亞甲基]-6-甲氧羰基-2-吲哚啉酮的晶型
CN110974787A (zh) 泊沙康唑干混悬剂及其制备方法
CN109463392A (zh) 一种呋虫胺油基种衣剂及其制备方法
JPS6284003A (ja) 水田用懸濁状除草剤組成物
SU931087A3 (ru) Способ индуцировани мужской стерильности у растений хлебных злаков и состав дл осуществлени
JPS6284002A (ja) 水田用懸濁状除草剤組成物
CN117426384B (zh) 一种烯效唑•调环酸钙悬浮剂及其制备方法和应用
US20210087192A1 (en) 1-Amino-triazolo(1,5-A)pyridine-substituted Urea Derivative and Uses Thereof
CN115735913A (zh) 一种温敏响应释放嘧菌酯纳米颗粒及其制备方法和应用
JPH06293607A (ja) 水懸濁型水田用除草剤
NO840560L (no) Vannopploeselig salt dannet av en syre og et alkaloid og anvendelse derav
CN117982434A (zh) 一种治疗湿性年龄相关性黄斑病变的对甲苯磺酸索拉非尼聚乳酸微球
CN105685070A (zh) 一种杀虫防病悬浮种衣剂
EP3582760A1 (en) Pharmaceutical composition comprising an antiemetic agent and method for the preparation thereof
Khandagale et al. Antifungal Activity of PLGA-Based Voriconazole Nanosuspension for Ophthalmic Application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190730